Adverum Biotechnologies Inc expected to post a loss of 36 cents a share - Earnings Preview

Adverum Biotechnologies

24/03/2023 22:33

* Adverum Biotechnologies Inc  ADVM.OQ   ADVM.O  is expected
to show no change in quarterly revenue when it reports 
results on March 27 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Adverum
Biotechnologies
Inc is for a loss of 36 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adverum
Biotechnologies Inc is $2.5​, above​ its last closing price
of $0.76. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.30       -0.34      -0.40     Missed  -15.9
 Jun. 30 2022  -0.36       -0.34      -0.44     Missed  -29.4
 Mar. 31 2022  -0.32       -0.31      -0.38     Missed  -22.6​
 Dec. 31 2021              -0.34      -0.35     Missed  -1.9
 ​​Sep.        -0.31       -0.37      -0.39     Missed  -4
 30 2021                                                
 Jun. 30 2021  -0.36       -0.39      -0.45     Missed  -15.7​
 Mar. 31 2021  -0.38       -0.38      -0.29     Beat    23.9
 Dec. 31 2020  -0.31       -0.32      -0.39     Missed  -20.7
 This summary was machine generated March 24 at 22:33 GMT.  All
figures in US dollars  unless otherwise stated